Cook Does Icahn's Dirty Work at Apple

Barely 6 months ago I contended that the intrusion of Carl Icahn into the company spelled the end of an era at Apple (AAPL).

Even before that point Apple had already shown that it was favoringfinancial engineering over the kind of engineering that enabled it to create a cash reserve in excess of $150 billion.

For those who cheered when it looked, from the surface, that Carl Icahn was retreating, having been prevented by Tim Cook from sacrificing corporate ethos for even more financial engineering, cheer no more.

As opposed to the 11th ever Icahn Tweet that told the world that he had amassed a “large position” in Apple, the most recent was  (self) – congratulatory.

With Apple’s post-earnings announcement of a 7 for 1 stock split and an 8% increase in the dividend, another nail has been put into a great company that is now evolving into what it had disdained in the past. In the absence of news that would excite investors and consumers alike, Apple has now continued its recent practice of pandering and diverting attention from what may be happening at the core of Apple.

It is in danger of becoming Microsoft (MSFT) of old, a company that was disparaged for its lack of product innovation and lack of coherent, forward looking leadership. Add to that a lack of a readily understandable strategy and you have a perfect target for hipsters and investors alike to bash and trash.

During that period, as Microsoft share price simply stayed in place, it routinely increased its dividend, at least doing something to appease shareholders. But while doing so it was roundly criticized for expensive and non-strategic acquisitions, which were deemed to be a waste of shareholder money.

However, I don’t make the comparison to Microsoft in a disparaging way. For those who practiced a covered option strategy, they were likely big fans of Microsoft, as treading in place is a great formula for generating lots of option premiums and is especially nice if there are dividends, as well.

In fact, perhaps if I compared Apple to the new Microsoft that many see as developing under the leadership of Satya Nadella, it might be viewed as being laudatory.

Ironically then, we now have today’s Apple.

The most common complaint heard is regarding its lack of innovation. Samsung may now be somewhat passe in its own right and Google (GOOG) may have a less than concretely defined strategy, but Apple has been widely admired for its innovation within a well developed strategy. The eco-system? While many didn’t understand its meaning in high school science, it was an obviously intuitive concept when it came to the Apple family of products, making so many wonder why no one had really mastered that concept before.

But the lack of new product introduction and expansion of that eco-system is troubling and has called into question Tim Cook’s leadership and vision.

Certainly news that sales of its iPad were well below projections can’t easily be interpreted in a positive light, as Apple also reported that its cash reserve fell this quarter, as more was returned to investors than was retained.

While innovation and leadership are now called into question evoking images of the old Microsoft, one has to also wonder how much shareholder cash Apple has squandered. No, not using the traditional Microsoft strategy of over-paying for poor strategic fitting entities, but rather through appeasement.

By waiting so long to pursue any share buy back strategy Apple has continually paid top dollar for shares, as pressure mounted for some use of its cash reserves. Under out-going CFO Peter Oppenheimer the strategy has been to buy shares when prices are high and there’s little doubt that share buy backs were accelerated to, in part, appease activists past and present.

While doing all of this, Apple has significantly under-performed the S&P 500 since August 2011, which is more than a year before it reached its peak share price. The comparisons get much worse after that date.

So that’s all bad, right?

While the days of Apple reaching $1,000/share (or $142.85 on a post-split basis) may be discussions of long ago, I think the opportunities for traders are as great or better than in recent memory.

Unless one believes that Apple can re-create its explosive share growth from 2009-2012, this is the time to look at Apple much in the way that Microsoft was able to reward some shareholders. Those were the shareholders who could look beyond the demand for share appreciation in return for using shares as a vehicle to create income streams through option premiums and dividends.

Sporting an attractive dividend and always attractive option premiums there is opportunity to capitalize on Apple’s signal that it is bidding farewell to that kind of share appreciation and is looking toward more mundane ways of pacifying those who would make noise. If it can’t be done through a shorter product cycle, through new products or ever increasing sales, it may as well be done by putting the obscenely large cash hoard to work in order to maintain a status quo and keep the activists at bay.

For the purists, it’s about the products. For a while it was also about being able to continually point at higher and higher stock prices and those great, unrealized gains. However, for those who simply view a stock as a vehicle toward realized profits the end of the era that started with Carl Icahn’s “failed” activism and that has resulted in Tim Cook’s capitulation, is now the time to consider the use of Apple in a covered option strategy.

For much of the decade prior to 2009 Apple was a great covered option trade. That era disappeared with its unidirectional price climb and returned a year ago as shares hit their near term lows.

While Icahn may have driven one nail into the purist’s heart and another into the coffin of the old Apple you knew and loved by re-directing attention from product to price, he has opened up the hearts of those that like lining their pockets with real gains.

I look forward to the more frequent trading of Apple now that we all know that the pretense of returning to the glory days is over.

Daily Market Update – April 23, 2014 (Close)

 

 

Daily Market Update – April 23, 2014 (Close)

While this morning looked to be a repeat of yesterday morning’s pre-open market, I’m reminded that yesterday was another in a string of days that the overall tone of the market doesn’t necessarily follow what goes on before the opening bell rings.

It looked to be another quiet trading day and it did turn out to be that way, but what couldn’t be lost is the size of some of the earnings related moves that appeared this week and early on this morning, both good and bad.

On the downside there were large moves in Lexmark, Cree and VMWare, while Netflix, YUM and others had strong gains.Of course, those YUM string gains evaporated very, very quickly with some negative guidance. At one point the turnaround was almost 10%

All of that bothers me, a little, seeing that the individual risk may be accentuated even as the market itself doesn’t appear to have elevated risk.

The key is that the market may not “appear” to have that risk. But since the market is nothing more than the sum of its component pieces, the more tenuous those pieces the greater the likelihood of weakness undoing some kind of foundation. It may not appear weak, but some of those component pieces are really on wobbly legs.

Many markets see their undoing come first with the same kind of exaggerated weakness shown in those stocks that had earlier showed exaggerated strength. We just recently went through a very short phase of seeing “Momentum” stocks under attack and a very strong drop in the NASDAQ.

The key here is that it was very short lived. The question is whether the drop was just a teaser for things to come. While seeing corrections is thought to be healthy for markets and consolidation is thought to be healthy for stocks, no one wants to be the only healthy one in the room. Owning shares of a stock undergoing price correction while everything else around you is going higher usually leads to more selling of an already down position.

That additional selling is one of those things that spooks markets, even though it may really be only germane to an individual stock or sector, such as biotechnology, or type of stock, such as “Momentum.”

The earnings releases from some of the more key components of the DJIA and S&P 500 haven’t been stellar, thus far, yet the market hasn’t reacted in any adverse way. Perhaps the key has been an abiding confidence that the Federal Reserve is still there to see to it that markets have some underpinning. What surprises me a little is that forward guidance hasn’t been reflecting any kind of optimism that might be expected in a growing economy.

While that has hurt those stocks the cynics will believe that companies are just setting themselves up for an “over-deliver” situation at the next quarter, but companies don’t seem to look that far in advance anymore.

With no really important economic news this week all you can do is speculate as to what these earnings mean for tomorrow and further down the road.

For now, at mid-week, and this being another slow week, I still don’t mind watching the bottom line grow, but I would much prefer to be an active participant.

I don’t know how many new opportunities may be identified during the rest of the week, but I’m not expecting much to happen, mostly hoping for some assignments to end the week and maybe using all of this unused time to start some kind of hobby.

Maybe photography.

I wonder if there’s a market for screenshots of my watch llst?

 

 

 

 

 

 

 

 



 

 

 

 

  

Daily Market Update – April 23, 2014

 

 

Daily Market Update – April 23, 2014 (10:00 AM)

While this morning looks to be a repeat of yesterday morning’s pre-open market, I’m reminded that yesterday was another in a string of days that the overall tone of the market doesn’t necessarily follow what goes on before the opening bell rings.

It looks to be another quiet trading day, but what can’t be lost is the size of some of the earnings related moves that are appearing, both good and bad.

On the downside there were large moves in Lexmark, Cree and VMWare, while Netflix, YUM and others had strong gains.

That bothers me, a little, that the risk may be accentuated even as the market itself doesn’t appear to have elevated risk.

The key is that the market may not “appear” to have that risk. But since the market is nothing more than the sum of its component pieces, the more tenuous those pieces the greater the likelihood of weakness undoing some kind of foundation.

Many markets see their undoing come first with the same kind of exaggerated weakness shown in those stocks that had earlier showed exaggerated strength. We just recently went through a very short phase of seeing “Momentum” stocks under attack and a very strong drop in the NASDAQ.

The key here is that it was very short lived. The question is whether the drop was just a teaser for things to come. While seeing corrections is thought to be healthy for markets and consolidation is thought to be healthy for stocks, no one wants to be the only healthy one in the room. Owning shares of a stock undergoing price correction while everything else around you is going higher usually leads to more selling of an already down position.

That additional selling is one of those things that spooks markets, even though it may really be only germane to an individual stock or sector, such as biotechnology, or type of stock, such as “Momentum.”

The earnings releases from some of the more key components of the DJIA and S&P 500 haven’t been stellar, thus far, yet the market hasn’t reacted in any adverse way. Perhaps the key has been an abiding confidence that the Federal Reserve is still there to see to it that markets have some underpinning. What surprises me a little is that forward guidance hasn’t been reflecting any kind of optimism that might be expected in a growing economy.

While that has hurt those stocks the cynics will believe that companies are just setting themselves up for an “over-deliver” situation at the next quarter, but companies don’t seem to look that far in advance anymore.

With no really important economic news this week all you can do is speculate as to what these earnings mean.

For now, at mid-week, and this being another slow week, I still don’t mind watching the bottom line grow, but I would much prefer to be an active participant.

I don’t know how many new opportunities may be identified during the rest of the week, but I’m not expecting much to happen, mostly hoping for some assignments to end the week and maybe using all of this unused time to start some kind of hobby.

 

 

 

 

 

 

 

 



 

 

 

 

  

Daily Market Update – April 22, 2014 (Close)

 

 

Daily Market Update – April 22, 2014 (Close)

Although the morning appeared to be getting ready to get off to a quiet start the morning started with more activist related news in a suddenly strong pharmaceutical sector that could have served as a catalyst to wake everyone up. With all of the recent negative news regarding high prices for pharmaceuticals, what was clear was that when it comes to discretionary health care, such as Botox and other cosmetic enhancers, no one is threatening congressional investigation into pricing structure.

On top of that today is a busy earnings day from some big names and it is also a Tuesday, which is once again a day that the market seems to want to go higher much more than on any other day.

I don’t recall the statistic, but I believe it was something on the order of more than 20 consecutive higher moving Tuesdays last year that is now finding a match, at least on statistical terms, with this year. While the consecutive streak is safe, at least for now, the likelihood of the market moving higher is as likely this year as it was last year and both years defied logic. Yet they both have created believers who will put aside other, more rationally based approaches, to go along for the ride that they presume will simply continue.

It’s often said that “hope is not a strategy,” yet many who should not be swayed by such things aren’t as dismissive of streaks, despite the fact that they may have as much basis as hope does.

When little is going on that may serve as a potential catalyst for markets, things like streaks, including the recent streak of the S&P 500 moving higher for six consecutive sessions, gets more and more attention.

After all of the recent concern about the market dropping, we’re now just 1% way from its high.

When the session was over, after having spent most of its time in tripe digit territory, we cut that distance from the closing high by nearly half.

That’s a pattern also, although not as newsworthy as consecutive streaks, but the market has just continued to be incredibly resilient regardless of what kind of news comes its way. That’s something that you can believe in. The market goes up to a new high, then begins a half-hearted correction and then moves on to another new high.

RInse and repeat.

I don’t know if any of this has meaning for me today, tomorrow or for the next generation of Tuesdays.

All of these discussions are fads of the moment.

By the time you jump onto the pharmaceutical ship, it will have sailed. The broad paint brush is usually only used right after some news breaks. After that there’s lots of luck involved in getting it right when a choice is made trying to find the next likely company to be a target of activism or takeover.

When it comes to betting on streaks, by the time you figure out how to reposition yourself to take advantage of any obvious streak it is just as likely to come to its logical conclusion.. Yet we get fascinated by these momentary blips and factoids, thinking that they offer great insights into what awaits down the road.

Clearly something had everyone fascinated today. I had only one trade that I tried to make all day and within seconds of entering it the price sailed higher, which is definitely not something you want in a Double DIvidend trade, which in this case would have been Bank of New York. Instead, I was happy to just watch most everything move higher, but still disappointed in being unable to sell calls on uncovered positions.

If today was not a Tuesday there would be no reason to believe that much was in store as even with earnings news coming out from those big names there isn’t too much impact. The market itself has little to move it in any direction at the moment, other than discussion of completely irrelevant streaks and statistical momentum that really doesn’t exist as anything other than wishful thinking.

Which is the same as hope.

Unfortunately, Tuesdays are followed by Wednesdays when the market is as likely to go up as it is to go down, just as it is during the three other days of the week.

Still, there’s probably something that can be hoped for as a short lived Tuesday has run its course.

I don’t know what that is, but I’m content to let the market get lifted higher by whatever mechanism it can use, but staying flat for the rest of the week would be especially nice.

Is asking for nothing extra asking for too much?

I hope not.

 

 

 

 

 

 

 



 

 

 

 

  

Daily Market Update – April 22, 2014

 

 

Daily Market Update – April 22, 2014 (10:00 AM)

Although the morning appears to be getting ready to get off to a quiet start the morning started with more activist related news in a suddenly strong pharmaceutical sector. With all of the recent negative news regarding high prices for pharmaceuticals, what was clear was that when it comes to discretionary health care, such as Botox and other cosmetic enhancers, no one is threatening congressional investigation into pricing structure.

On top of that today is a busy earnings day from some big names and it is also a Tuesday, which is once again a day that the market seems to want to go higher much more than on any other day.

I don’t recall the statistic, but I believe it was something on the order of more than 20 consecutive higher moving Tuesdays last year that is now finding a match, at least on statistical terms, with this year. While the consecutive streak is safe, at least for now, the likelihood of the market moving higher is as likely this year as it was last year and both years defied logic. Yet they both have created believers who will put aside other, more rationally based approaches, to go along for the ride that they presume will simply continue.

It’s often said that “hope is not a strategy,” yet many who should not be swayed by such things aren’t as dismissive of streaks, despite the fact that they may have as much basis as hope does.

When little is going on that may serve as a potential catalyst for markets, things like streaks, including the recent streak of the S&P 500 moving higher for six consecutive sessions, gets more and more attention.

After all of the recent concern about the market dropping, we’re now just 1% way from its high.

That’s a pattern also, although not as newsworthy as consecutive streaks, but the market has just continued to be incredibly resilient regardless of what kind of news comes its way. That’s something that you can believe in.

I don’t know if any of this has meaning for me today, tomorrow or for the next generation of Tuesdays.

All of these discussions are fads of the moment.

By the time you jump onto the pharmaceutical ship, it will have sailed. The broad paint brush is usually only used right after some news breaks. After that there’s lots of luck involved in getting it right when a choice is made trying to find the next likely company to be a target of activism or takeover.

When it comes to betting on streaks, by the time you figure out how to reposition yourself to take advantage of any obvious streak it is just as likely to come to its logical conclusion.. Yet we get fascinated by these momentary blips and factoids, thinking that they offer great insights into what awaits down the road.

If today was not a Tuesday there would be no reason to believe that much was in store as even with earnings news coming o
ut from those big names there isn’t too much impact. The market itself has little to move it in any direction at the moment, other than discussion of completely irrelevant streaks and statistical momentum that really doesn‘t exist as anything other than wishful thinking.

Which is the same as hope.